NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details 7) (USD $) In Thousands, except Per Share data, unless otherwise specified
|
0 Months Ended |
12 Months Ended |
0 Months Ended |
Dec. 01, 2014
|
Sep. 19, 2014
|
Aug. 29, 2014
|
Jun. 26, 2014
|
Jun. 02, 2014
|
Apr. 07, 2014
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Aug. 25, 2014
|
Strategic Alliance and Formation of China Joint Venture [Line Items] |
|
|
|
|
|
|
|
|
|
|
Payments of Dividends |
$ 1,871us-gaap_PaymentsOfDividends
|
$ 28,501us-gaap_PaymentsOfDividends
|
$ 1,619us-gaap_PaymentsOfDividends
|
|
$ 1,619us-gaap_PaymentsOfDividends
|
$ 1,618us-gaap_PaymentsOfDividends
|
$ 35,228us-gaap_PaymentsOfDividends
|
$ 30,419us-gaap_PaymentsOfDividends
|
$ 2,349us-gaap_PaymentsOfDividends
|
|
Premium to Entity Average Stock Price for the Trailing Thirty Day Period |
|
|
|
10.00%natr_PremiumToEntityAverageStockPriceForTrailingThirtyDayPeriod
|
|
|
|
|
|
|
Fosun Pharma [Member] |
|
|
|
|
|
|
|
|
|
|
Strategic Alliance and Formation of China Joint Venture [Line Items] |
|
|
|
|
|
|
|
|
|
|
Shares, Issued |
|
|
|
|
|
|
|
|
|
2,855us-gaap_SharesIssued / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = natr_FosunPharmaMember
|
Share Price |
|
|
|
|
|
|
|
|
|
$ 16.19us-gaap_SharePrice / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = natr_FosunPharmaMember
|
Period of Time to Measure Premium of Entity Common Stock |
|
|
|
30 days
|
|
|
|
|
|
|
Related Party Ownership Percentage After Common Stock Purchase |
|
|
|
|
|
|
|
|
|
15.00%natr_RelatedPartyOwnershipPercentageAfterCommonStockPurchase / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = natr_FosunPharmaMember
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
Strategic Alliance and Formation of China Joint Venture [Line Items] |
|
|
|
|
|
|
|
|
|
|
Dividends Payable, Amount Per Share |
|
|
|
|
|
|
|
|
|
$ 1.50us-gaap_DividendsPayableAmountPerShare / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember
|
Dividends payable to shareholders |
|
|
|
|
|
|
|
|
|
28,501natr_DividendsPayableToShareholders / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember
|
Common Stock | Fosun Pharma [Member] |
|
|
|
|
|
|
|
|
|
|
Strategic Alliance and Formation of China Joint Venture [Line Items] |
|
|
|
|
|
|
|
|
|
|
Proceeds from Issuance of Private Placement |
|
|
|
|
|
|
|
|
|
44,795us-gaap_ProceedsFromIssuanceOfPrivatePlacement / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = natr_FosunPharmaMember / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember
|
China Joint Venture [Member] |
|
|
|
|
|
|
|
|
|
|
Strategic Alliance and Formation of China Joint Venture [Line Items] |
|
|
|
|
|
|
|
|
|
|
Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions |
|
|
|
|
|
|
|
|
|
80.00%us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions / dei_LegalEntityAxis = natr_ChinaJointVentureMember
|
Initial Capitalization Amount |
|
|
|
|
|
|
|
|
|
20,000natr_InitialCapitalizationAmount / dei_LegalEntityAxis = natr_ChinaJointVentureMember
|
China Joint Venture [Member] | Fosun Pharma [Member] |
|
|
|
|
|
|
|
|
|
|
Strategic Alliance and Formation of China Joint Venture [Line Items] |
|
|
|
|
|
|
|
|
|
|
Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions |
|
|
|
|
|
|
|
|
|
20.00%us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions / dei_LegalEntityAxis = natr_ChinaJointVentureMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = natr_FosunPharmaMember
|
Initial Capitalization Amount |
|
|
|
|
|
|
|
|
|
$ 16,000natr_InitialCapitalizationAmount / dei_LegalEntityAxis = natr_ChinaJointVentureMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = natr_FosunPharmaMember
|
Number of Board of Directors Initially Appointed |
|
|
|
|
|
|
|
|
|
1natr_NumberOfBoardOfDirectorsInitiallyAppointed / dei_LegalEntityAxis = natr_ChinaJointVentureMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = natr_FosunPharmaMember
|